Core Viewpoint - Jin Cheng Pharmaceutical (300233.SZ) announced on October 9 that its actual controller and chairman, Zhao Yeqing, received a notice from the China Securities Regulatory Commission (CSRC) regarding allegations of market manipulation, as indicated in the administrative penalty notice [1][3]. Group 1: Allegations and Penalties - Zhao Yeqing, Wang Zhen, and Liu Feng are accused of violating Article 77 of the Securities Law of 2005, constituting market manipulation as per Article 203 of the same law [3]. - The proposed penalties include a total fine of 3 million yuan, with Zhao Yeqing responsible for 1.5 million yuan, Wang Zhen for 1.2 million yuan, and Liu Feng for 300,000 yuan [3]. - Zhao Yeqing will face a 4-year market ban, while Wang Zhen will be banned for 3 years, preventing them from engaging in securities business or holding positions in any public companies during the ban period [3]. Group 2: Previous Penalties - On March 12, 2025, Zhao Yeqing received a prior notice proposing the confiscation of illegal gains amounting to approximately 15.4391 million yuan, with Zhao Yeqing's share being 7.7196 million yuan [4]. - The previous proposed penalties included fines totaling approximately 46.3174 million yuan, with Zhao Yeqing liable for 23.1587 million yuan [4]. - The current proposed penalties are significantly lower than the previous ones, indicating a potential change in the regulatory approach or the circumstances surrounding the case [4]. Group 3: Company Overview - Jin Cheng Pharmaceutical was established in 2011 and is listed on the Shenzhen Stock Exchange's Growth Enterprise Market, employing over 3,900 people and operating more than 30 subsidiaries globally [8]. - The company specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, drug formulations, and health products, and is recognized for its production of cephalosporin intermediates and other pharmaceutical products [8]. - Jin Cheng Pharmaceutical is a well-known manufacturer of anti-infection and women's health medications, with a comprehensive product line in the lifecycle of women's health [8].
因违法违规行为,金城医药董事长拟被罚150万元、禁入市场4年